Recent News

• 03.18.2025 - MiNK Therapeutics Fourth Quarter 2024 Financial Results
• 03.18.2025 - MiNK Therapeutics Fourth Quarter 2024 Financial Results
• 03.04.2025 - MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
• 03.04.2025 - MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
• 02.24.2025 - MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
• 02.24.2025 - MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
• 02.20.2025 - MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
• 02.20.2025 - MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
• 02.12.2025 - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
• 02.12.2025 - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Recent Filings

• 01.21.2025 - 8-K Current report
• 12.20.2024 - DEF 14A Other definitive proxy statements
• 12.09.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.09.2024 - 3 Initial statement of beneficial ownership of securities